Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Metrics: PDF 4487 views | HTML 3117 views | ?
Nobuo Tsuchida1, Avaniyapuram Kannan Murugan2 and Michele Grieco3
1 Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University, Yushima, Bunkyo-ku, Tokyo, Japan
2 Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3 DiSTABiF, Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Seconda Università di Napoli, Caserta, Italy
Nobuo Tsuchida, email:
Keywords: Kirsten ras, K-ras, KRAS, human cancer, oncogene, EGFR-targeted therapy
* Ras oncogene is written in this paper as: ras for viral origin, RAS for human origin and Ras for both viral and human origins
Received: October 01, 2015 Accepted: April 10, 2016 Published: April 17, 2016
The KRAS/ K-RAS oncogene is crucially involved in human cancer. The term “oncogene” – i.e., a gene able to transform a normal cell into a tumor cell – was introduced in 1969, but the word was not used in the human carcinogenesis literature until much later. Transforming Kras and Hras oncogenes from the Kirsten and Harvey sarcoma viruses were not identified until the early 1980s due to the complicated structures of the viral genomes. Orthologs of these viral oncogenes were then found in transforming DNA fragments in human cancers in the form of mutated versions of the HRAS and KRAS proto-oncogenes. Thus, RAS genes were the first human oncogenes to be identified. Subsequent studies showed that mutated KRAS acted as an in vivo oncogenic driver, as indicated by studies of anti-EGFR therapy for metastatic colorectal cancers. This review addresses the historical background and experimental studies that led to the discovery of Kirsten Ras as an oncogene, the role of mutated KRAS in human carcinogenesis, and recent therapeutic studies of cancer cells with KRAS mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.